We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.45B
$71M 0.35%
2,454,082
– –
TIL icon
27
Instil Bio
TIL
$49M
$66.6M 0.32%
194,685
– –
MRUS
28
DELISTED
Merus
MRUS
$64.8M 0.32%
2,037,469
– –
HZNP
29
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$64.6M 0.31%
599,110
– –
IMTX icon
30
Immatics
IMTX
$1.23B
$59.5M 0.29%
4,423,731
– –
CCXI
31
DELISTED
ChemoCentryx, Inc.
CCXI
$59.4M 0.29%
1,631,266
+1,330,071
+442% +$46.7M
INSM icon
32
Insmed
INSM
$22.4B
$58.7M 0.29%
2,156,001
– –
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.2B
$57.7M 0.28%
676,975
– –
KRYS icon
34
Krystal Biotech
KRYS
$10.7B
$56.5M 0.27%
807,735
+200,000
+33% +$11.6M
VERV
35
DELISTED
Verve Therapeutics
VERV
$52.2M 0.25%
1,416,530
– –
VSTM icon
36
Verastem
VSTM
$528M
$44.1M 0.21%
1,790,969
– –
RYTM icon
37
Rhythm Pharmaceuticals
RYTM
$7.31B
$38.6M 0.19%
3,863,239
– –
KDNY
38
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$38.1M 0.19%
2,334,102
+431,033
+23% +$6.14M
RARE icon
39
Ultragenyx Pharmaceutical
RARE
$2.46B
$37.4M 0.18%
444,444
– –
ADAP
40
DELISTED
Adaptimmune Therapeutics
ADAP
$36.9M 0.18%
9,830,877
– –
ALKS icon
41
Alkermes
ALKS
$8.09B
$34.9M 0.17%
1,500,000
+271,830
+22% +$7.15M
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$6.23B
$33M 0.16%
2,799,577
– –
DSGN icon
43
Design Therapeutics
DSGN
$750M
$30.8M 0.15%
1,436,636
– –
TLIS
44
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$30.6M 0.15%
508,322
+3,333
+0.7% +$249K
FMTX
45
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$28.8M 0.14%
2,024,876
– –
ZYME icon
46
Zymeworks
ZYME
$1.62B
$28M 0.14%
1,708,472
– –
BLUE
47
DELISTED
bluebird bio
BLUE
$25M 0.12%
124,986
-67,992
-35% -$16M
ALGS icon
48
Aligos Therapeutics
ALGS
$26.3M
$24.6M 0.12%
83,056
– –
OPT
49
DELISTED
Opthea Limited American Depositary Shares
OPT
$24.1M 0.12%
3,196,191
-186,606
-6% -$1.36M
CRNX icon
50
Crinetics Pharmaceuticals
CRNX
$8.88B
$23.5M 0.11%
827,480
-93,176
-10% -$2.3M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.